Clinical tumor lysis syndrome associated with elranatamab in relapsed multiple myeloma: a case report
Martín Milanesio1, Julieta Olmedo1, Gastón Caeiro1
1Hospital Privado.
Introduction:
Multiple Myeloma (MM) is currently an incurable disease, with constant relapses and the need for multiple lines of treatment. Immune therapies, which include bispecific antibodies such as elranatamab, are a new option for the treatment of patients with relapsed/refractory MM (R/R MM), with high effectiveness, but not free of adverse reactions. Tumor lysis syndrome (TLS) is a rare complication of MM treatment and has not been reported after application of elranatamab.
Case Presentation:
We report the case of a man with R/R MM who presented TLS after application of the first dose of elranatamab. The TLS resolved after supportive measures without subsequent recurrence.
Conclusion:
TLS is an uncommon complication of MM treatment and could be triggered by bispecific antibodies.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
